Orgenesis Inc. · OTC:ORGS
Orgenesis — Investor Presentation (February 2022)
32 slides from Orgenesis's investor presentation, February 2022

Slide 1: Investor Presentation
N A S D A Q : O R G S I N V E S T O R P R E S E N T A T I O N ORGENESIS

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements in

Slide 3: About us
Orgenesis is global biotech company committed to About us transforming the processing of cell and gene therapies (CGT) by accelerating clinical development and commercialization through a POCare Platform 10 years Global footprint Operating in 15 Publicly traded of experience US, EU, Israel & S.Korea

Slide 4: Corporate Milestones
Corporate Established 2011 Milestones 2012 Initiated Metabolic R&D activity 2013 Expanded therapeutic R&D activity 2014 Commencing CDMO activity through a fully owned subsidiary, MaSTherCell 2015 Viral vector processing capabilities for internal needs 2016 Initiated delivery technologies 2017 Initia

Slide 5: Achievements
Achievements Built contract development manufacturing organization (CDMO) MaSTherCell from ~$3 million to >$33 million 01 revenue in 5 years (2014-2019) and sold for $315 million in February 2020 with net proceeds of $127 million Developed a three component POCare Platform as 02 a harmonized framewo

Slide 6: What are Cell & Gene Therapies
What are Cell & Gene Therapies Traditional biopharmaceutical treatments use proteins for therapeutic applications Cell therapies use manipulated genes and cells for therapeutic applications Autologous cell and gene therapies use a patient’s own cells to create the treatment ORGENESIS / 6

Slide 7: Cell & Gene Therapies – Market Growth
Cell & Gene Therapies – Market Growth Regenerative Medicine Market size ( $bn) Global Industry-Sponsored Cell & Gene Therapeutic Clinical Trials $149.8 ~1,320 Clinical trials Underway 23.5% CAGR 1% 2% 4% 2021 – 2028 17% 24% 28% 30% $27.7 163 438 41% 719 Phase 1 Phase 2 47% Phase 3 33% 21% 52% 2020 2

Slide 8: Cell & Gene Therapies – Services
Cell & Gene Therapies – Services Enormous market potential 2020 global market size for CGT manufacturing was $2.7 bn and is projected to reach $11.2 bn by 2027 Global Market for CGT Manufacturing by CMO/CDMOs, 2020-2027 4.9 2.8 2.7 2.2 2.2 1.7 1.5 1.3 1.5 1.2 1.2 1.0 0.9 0.6 0.5 0.8 0.5 0.7 0.8 0.4

Slide 9: Industry Landscape Today
Industry Landscape Today 2,648# trials industry & non-industry sponsored groups ~50# average annual batches / trial of indications are in oncology ~132,400 annual batches Oncology* 1,354 Metabolic disorders* 70 ~50/50 industry vs. non-Industry sponsored groups Infectious diseases* 166 Ophtalmology 6

Slide 10: What’s Holding CGTs Back?
What’s Holding CGTs Back? Centralized, non-automated processes that are high risk, high cost and have complicated logistics. These innovative drugs ultimately cannot be commercialized because of the complexity and cost. Need for more efficient and cost-effective manufacturing model COSTS SCALABILITY

Slide 11: The POCare Platform – Our Solution to an Emerging Industry
The POCare Platform – Our Solution to an Emerging Industry The Orgenesis POCare Platform is built on three components to expedite development and production of advanced medicines. POCare Therapies: Licensed therapies provided for direct hospital supply Therapies POCare Technology: Closed, automated

Slide 12: Value Creation Assets
Value Creation Assets The services we provide The therapies we provide The technologies we use Harmonized Global POCare Processing Capacities / Immuno-oncology therapies Orgenesis MD POCare Umbrella / OMPULS Maryland GMP implementation & operation / Metabolic therapies / Automation (Processing, QC)

Slide 13: Orgenesis is Unlocking the Potential of CGT
Orgenesis is Unlocking Orgenesis POCare Platform the Potential of CGT Localized POCare centers, mobile processing solutions eliminate complicated logistics and Available reduce process risk at a reduced price Process development is focused on quality control (QC), regulatory compliance and harmoniza

Slide 14: Harmonization of Supply at POCare Centers
Harmonization of Supply at POCare Centers Design Global and Adapt Local Key Principles Through Global Quality Harmonization standards aimed at Global QA system ensuring quality comparability across the network and application of good practices (GxP) across all activities and throughout therapy lifec

Slide 15: POCare Centers at a Glance
POCare Centers at a Glance Where we process, develop and supply Orgenesis Belgium Orgenesis Biotech IL Orgenesis Korea Orgenesis Biotech IL Wolfson Medical Center, Belgium Israel Korea Validation site, Israel BIO-ISOLATOR CLOSED CONTAINMENT SYSTEM PROCESS DEVELOPMENT LABS cGMP CLEANROOM OMPUL A/B OR

Slide 16: OMPUL I Orgenesis Mobile Processing Units and Labs
OMPUL I Orgenesis Mobile Processing Units and Labs ORGENESIS / 16

Slide 17: OMPUL
OMPUL OMPUL approach is focusing on three innovative pillars: Orgenesis Mobile Processing Units and Labs Orgenesis specializes in development of engineered solutions Mobile clean rooms for complex biological processes in point of care CGT processing by developing OMPUL to be a fully integrated, clos

Slide 18: Inside the OMPUL
Inside the OMPUL ORGENESIS / 18

Slide 19: POCare Global Spread
POCare Global Spread , Hospital exemption, investigator trials supplying ATMP products for Directly or indirectly through biotech companies licensing hospitals Regional partnership to scale-out & up GMP capacities 10# partners & directly, Progressive roll-out up to 16# centres , with ~5- 10# OMPUL u

Slide 20: POCare Centers - Revenue Phasing
POCare Centers - Revenue Phasing Contracts: typically 4-8 quarters per activity Activity 1# : Process development and technology transfer are the first critical steps of collaboration Activity 2# : GMP processing (Operations, QC, QA/QP, logistics) ENGINEERING QUALIFICATION ASEPTIC PROCESS DOCUMENT O

Slide 21: POCare Capacity Roll-Out
POCare Capacity Roll-Out POCare Country 2021 2022-4 Name Australia 1 Belgium 1 China 1 Germany 1 Greece 1 India 1 Israel 1 Italy 1 Korea, republic of 1 Slovenia 1 Spain 1 The Netherlands 1 USA 2 2 Total 7 9 ORGENESIS / 21

Slide 22: POCare Capacity Build-Out
POCare Capacity Build-Out 10 Regional Partners & Direct 16 POCare centers 5-10 OMPULs each based on capacity planning 100 batches / OMPUL (therapy process dependent) ~$100,000 ATMP price (therapy/indication dependent) ORGENESIS / 22

Slide 23: Products Currently Serviced by POCare
Products Currently Serviced by POCare Program Indications Preclinical IND Enabling Studies Clinical Trials Clinical Use Immuno-Oncology ORGCAR19 (CD19 CAR-T) B-ALL, Lymphoma Celyvir Neuroblastoma MOTC (Metabolic Optimized T-Cells) Lung Cancer; Melanoma DUVAC (Cellular Vaccine) Solid Tumors; Pancreat

Slide 24: Metabolically Optimized T Cells
Metabolically Optimized T Cells (MOTC) TILs Therapy – Clinical/Commercial Stage Adoptive cell therapy (ACT) using Tumor-Infiltrating Lymphocytes (TILs) for metastatic melanoma patients / Autologous CD4+ and CD8+ T lymphocytes expanded from tumors in the presence of interleukin-2 (IL-2) alone, or in

Slide 25: Autologous CD19 CAR-T Therapy
Autologous CD19 CAR-T Therapy Autologous Products for the Treatment of Osteoarthritis GS linker VL VH / B-ALL is an aggressive neoplasm of B-lymphocyte precursors that express the pan-B- scFv cell marker CD19 in almost all cases. CD8 hinge / The therapy targets a unique sequence of CD-19 inducing a

Slide 26: DUVAC (Dual Vaccination Therapy)
DUVAC (Dual Vaccination Therapy) Anti-tumor Immunity Induction Antigen presenting cells based anti-cancer immunotherapy targeting Intradermal Blood Tumor-Associated Antigens (TAAs) for hard-to-treat solid tumors injections Collection / Dual vaccine cell-based immunotherapy harnesses the immune syste

Slide 27: Cartil-S/Chondroseal
Cartil-S/Chondroseal Small biopsy of Autologous Products for the Treatment of Osteoarthritis Adipose tissue Therapy / Osteoarthritis occurs due to cartilage defects of degenerative origin. / Cartil-S is an autologous injectable product that helps delay/stop the progression of osteoarthritis, involvi

Slide 28: Kyslecel
KyslecelTM Autologous Pancreatic-derived Islets for Auto-transplantation Pancreas resected from patient Therapy / Chronic Pancreatitis is an inflammatory painful condition, leading to pancreas degeneration and diabetes in most patients. / KyslecelTM is made from the patient’s own insulin-producing p

Slide 29: Financial Highlights - Strong Revenue Growth
Financial Highlights - Strong Revenue Growth Quarterly revenue First nine months revenue ($ in millions) ($ in millions) $28.6 5.4x $8.7 5.1x $5.3 $1.7 Q3 2020 Q3 2021 9M 2020 9M 2021 ORGENESIS / 29

Slide 30: Key Statistics
Key Statistics Stock Information Listing NASDAQ Symbol ORGS Share Structure Shares Outstanding (as of August 5, 2021) $ 24.5 M Market Cap (as of November 8, 2021) $ 108.5 M Cash & Cash Equivalents $ 15 M Long-Term Debt (at $7/share conversion) $ 7.3 M Ownership of Directors & Executive Officers (as

Slide 31: Meet our Board of Directors
Meet our Board of Directors Vered Caplan Yaron Adler Ashish Nanda Board Chairman & CEO Board Director Board Director Guy Yachin David Sidransky Mario Phillips Board Director Board Director Board Director ORGENESIS / 31

Slide 32: Together we can make cell and gene therapy accessible to all.
Together we can make cell and gene therapy accessible to all. Thank you ORGENESIS / 32
Source: Internet Archive copy of ir.orgenesis.com
More decks from Orgenesis Inc.
Investor Presentation (August 2024)18 slides · Aug 29, 2024
Investor Presentation (May 2024)22 slides · May 2024
Investor Presentation (July 2022)29 slides · July 2022
Investor Presentation (April 2022)32 slides · April 2022
Investor Presentation (2021)23 slides · Feb 5, 2021
Investor Presentation (November 2020)23 slides · Nov 12, 2020